5
|
Brinck JW, Thomas A, Lauer E, Jornayvaz FR, Brulhart-Meynet MC, Prost JC, Pataky Z, Löfgren P, Hoffstedt J, Eriksson M, Pramfalk C, Morel S, Kwak BR, van Eck M, James RW, Frias MA. Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection. Arterioscler Thromb Vasc Biol 2016; 36:817-24. [PMID: 26966278 DOI: 10.1161/atvbaha.115.307049] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Accepted: 02/29/2016] [Indexed: 11/16/2022]
Abstract
OBJECTIVE The dyslipidemia of type 2 diabetes mellitus has multiple etiologies and impairs lipoprotein functionality, thereby increasing risk for cardiovascular disease. High-density lipoproteins (HDLs) have several beneficial effects, notably protecting the heart from myocardial ischemia. We hypothesized that glycation of HDL could compromise this cardioprotective effect. APPROACH AND RESULTS We used in vitro (cardiomyocytes) and ex vivo (whole heart) models subjected to oxidative stress together with HDL isolated from diabetic patients and nondiabetic HDL glycated in vitro (methylglyoxal). Diabetic and in vitro glycated HDL were less effective (P<0.05) than control HDL in protecting from oxidative stress. Protection was significantly, inversely correlated with the degree of in vitro glycation (P<0.001) and the levels of hemoglobin A1c in diabetic patients (P<0.007). The ability to activate protective, intracellular survival pathways involving Akt, Stat3, and Erk1/2 was significantly reduced (P<0.05) using glycated HDL. Glycation reduced the sphingosine-1-phosphate (S1P) content of HDL, whereas the S1P concentrations of diabetic HDL were inversely correlated with hemoglobin A1c (P<0.005). The S1P contents of in vitro glycated and diabetic HDL were significantly, positively correlated (both <0.01) with cardiomyocyte survival during oxidative stress. Adding S1P to diabetic HDL increased its S1P content and restored its cardioprotective function. CONCLUSIONS Our data demonstrate that glycation can reduce the S1P content of HDL, leading to increased cardiomyocyte cell death because of less effective activation of intracellular survival pathways. It has important implications for the functionality of HDL in diabetes mellitus because HDL-S1P has several beneficial effects on the vasculature.
Collapse
Affiliation(s)
- Jonas W Brinck
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.).
| | - Aurélien Thomas
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Estelle Lauer
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - François R Jornayvaz
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Marie-Claude Brulhart-Meynet
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Jean-Christophe Prost
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Zoltan Pataky
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Patrik Löfgren
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Johan Hoffstedt
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Mats Eriksson
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Camilla Pramfalk
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Sandrine Morel
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Brenda R Kwak
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Miranda van Eck
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Richard W James
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| | - Miguel A Frias
- From the Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition, Medical Faculty, Geneva University, Geneva, Switzerland (J.W.B., F.R.J., M.-C.B.-M., R.W.J., M.A.F.); University Centre of Legal Medicine, Unit of Toxicology, Lausanne-Geneva, Switzerland (A.T., E.L., J.-C.P.); Faculty of Biology and Medicine, Lausanne University Hospital, Lausanne University, Lausanne, Switzerland (A.T.); Department of Community Medicine, Service of Therapeutic Education for Chronic Diseases, WHO Collaborating Centre, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland (Z.P.); Department of Medicine, Karolinska Institute, Stockholm, Sweden (J.W.B., P.L., J.H., M.E.); Molecular Nutrition Unit, Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden (C.P.); Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (C.P.); Department of Pathology and Immunology, Medical Faculty, Geneva University, Geneva, Switzerland (S.M., B.R.K.); and Leiden Academic Centre for Drug Research, Division of Biopharmaceutics, Cluster of BioTherapeutics, Leiden University, Leiden, The Netherlands (M.v.E.)
| |
Collapse
|
12
|
Thanabalasingham G, Huffman JE, Kattla JJ, Novokmet M, Rudan I, Gloyn AL, Hayward C, Adamczyk B, Reynolds RM, Muzinic A, Hassanali N, Pucic M, Bennett AJ, Essafi A, Polasek O, Mughal SA, Redzic I, Primorac D, Zgaga L, Kolcic I, Hansen T, Gasperikova D, Tjora E, Strachan MW, Nielsen T, Stanik J, Klimes I, Pedersen OB, Njølstad PR, Wild SH, Gyllensten U, Gornik O, Wilson JF, Hastie ND, Campbell H, McCarthy MI, Rudd PM, Owen KR, Lauc G, Wright AF. Mutations in HNF1A result in marked alterations of plasma glycan profile. Diabetes 2013; 62:1329-37. [PMID: 23274891 PMCID: PMC3609552 DOI: 10.2337/db12-0880] [Citation(s) in RCA: 80] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2012] [Accepted: 10/17/2012] [Indexed: 12/31/2022]
Abstract
A recent genome-wide association study identified hepatocyte nuclear factor 1-α (HNF1A) as a key regulator of fucosylation. We hypothesized that loss-of-function HNF1A mutations causal for maturity-onset diabetes of the young (MODY) would display altered fucosylation of N-linked glycans on plasma proteins and that glycan biomarkers could improve the efficiency of a diagnosis of HNF1A-MODY. In a pilot comparison of 33 subjects with HNF1A-MODY and 41 subjects with type 2 diabetes, 15 of 29 glycan measurements differed between the two groups. The DG9-glycan index, which is the ratio of fucosylated to nonfucosylated triantennary glycans, provided optimum discrimination in the pilot study and was examined further among additional subjects with HNF1A-MODY (n = 188), glucokinase (GCK)-MODY (n = 118), hepatocyte nuclear factor 4-α (HNF4A)-MODY (n = 40), type 1 diabetes (n = 98), type 2 diabetes (n = 167), and nondiabetic controls (n = 98). The DG9-glycan index was markedly lower in HNF1A-MODY than in controls or other diabetes subtypes, offered good discrimination between HNF1A-MODY and both type 1 and type 2 diabetes (C statistic ≥ 0.90), and enabled us to detect three previously undetected HNF1A mutations in patients with diabetes. In conclusion, glycan profiles are altered substantially in HNF1A-MODY, and the DG9-glycan index has potential clinical value as a diagnostic biomarker of HNF1A dysfunction.
Collapse
Affiliation(s)
- Gaya Thanabalasingham
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K
- Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, U.K
| | - Jennifer E. Huffman
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, U.K
| | - Jayesh J. Kattla
- Dublin-Oxford Glycobiology Laboratory, National Institute for Bioprocessing Research and Training (NIBRT), Dublin, Ireland
| | | | - Igor Rudan
- Centre for Population Health Sciences, University of Edinburgh Medical School, Edinburgh, U.K
- University of Split School of Medicine, Split, Croatia
| | - Anna L. Gloyn
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K
- Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, U.K
| | - Caroline Hayward
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, U.K
| | - Barbara Adamczyk
- Dublin-Oxford Glycobiology Laboratory, National Institute for Bioprocessing Research and Training (NIBRT), Dublin, Ireland
| | - Rebecca M. Reynolds
- Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, U.K
| | - Ana Muzinic
- Genos Ltd., Glycobiology Division, Zagreb, Croatia
| | - Neelam Hassanali
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K
| | - Maja Pucic
- Genos Ltd., Glycobiology Division, Zagreb, Croatia
| | - Amanda J. Bennett
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K
| | - Abdelkader Essafi
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, U.K
| | - Ozren Polasek
- University of Split School of Medicine, Split, Croatia
| | - Saima A. Mughal
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K
- Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, U.K
| | - Irma Redzic
- Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
| | - Dragan Primorac
- University of Split School of Medicine, Split, Croatia
- University of Osijek School of Medicine, Osijek, Croatia
| | - Lina Zgaga
- Centre for Population Health Sciences, University of Edinburgh Medical School, Edinburgh, U.K
| | - Ivana Kolcic
- University of Split School of Medicine, Split, Croatia
| | - Torben Hansen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
- Steno Diabetes Center, Gentofte, Denmark
| | - Daniela Gasperikova
- DIABGENE and Diabetes Laboratory, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia
| | - Erling Tjora
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
| | | | - Trine Nielsen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Juraj Stanik
- DIABGENE and Diabetes Laboratory, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia
- Children Diabetes Centre at the First Department of Paediatrics, Faculty of Medicine at the Comenius University, Bratislava, Slovakia
| | - Iwar Klimes
- DIABGENE and Diabetes Laboratory, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia
| | - Oluf B. Pedersen
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark
- Hagedorn Research Institute, Copenhagen, Denmark
| | - Pål R. Njølstad
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
| | - Sarah H. Wild
- Centre for Population Health Sciences, University of Edinburgh Medical School, Edinburgh, U.K
| | - Ulf Gyllensten
- Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
| | - Olga Gornik
- Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
| | - James F. Wilson
- Centre for Population Health Sciences, University of Edinburgh Medical School, Edinburgh, U.K
| | - Nicholas D. Hastie
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, U.K
| | - Harry Campbell
- Centre for Population Health Sciences, University of Edinburgh Medical School, Edinburgh, U.K
| | - Mark I. McCarthy
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K
- Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, U.K
- Wellcome Trust for Human Genetics, University of Oxford, Oxford, U.K
| | - Pauline M. Rudd
- Dublin-Oxford Glycobiology Laboratory, National Institute for Bioprocessing Research and Training (NIBRT), Dublin, Ireland
| | - Katharine R. Owen
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K
- Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, U.K
| | - Gordan Lauc
- Genos Ltd., Glycobiology Division, Zagreb, Croatia
- Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
| | - Alan F. Wright
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, U.K
| |
Collapse
|